A Controlled, Double-Blind Study of dl-Alpha-Tocopheryl Nicotinate (Juvela-Nicotinate®) for Treatment of Symptoms in Hypertension and Cerebral Arteriosclerosis

Publisher Website
Google Scholar
Abstract
A controlled, double-blind study of effects of dl-.alpha.-tocopheryl nicotinate (vitamin E-nicotinate: EN) for relief of symptoms was performed in 94 patients with hypertension and cerebral arteriosclerosis. Most cases (89) (44 cases treated with EN and 45 with inactive placebo) had completed this study. Six capsules of EN (600 mg) in the treated group and 6 capsules of inactive placebo in the placebo group were given daily for 4 wk in all cases, and for 6 wk in 43 cases. The general improvement rating was significantly greater in EN group than that in placebo group (P < 0.005). For 5 items of subjective symptoms, the improvement rating of EN was relatively higher than that of placebo: numbness of limbs (P = 0.032), dizziness (P = 0.054), stiff neck (P < 0.10), heavy feeling of head (P < 0.10) and insomnia (P = 0.025). The general improvement rating increased consistently as related to time intervals following treatment in EN group as follows: 73.7% at 2 wk, 87.2% at 4 wk and 95.2% at 6 wk intervals. The placebo group was essentially the same at each time interval as follows; 68.6% at 2 wk, 61.1% at 4 wk and 63.6% at 6 wk intervals, respectively. No untoward side effects from this agent were observed during the study, but a few cases experienced mild anorexia, diarrhea or abdominal discomfort. EN appears to be a safe and effective agent for relieving various symptoms attributed to hypertension and cerebral arteriosclerosis.

This publication has 0 references indexed in Scilit: